Cliniques Universitaires Saint-Luc

Running trials

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Comparison of Neurocognitive Outcome in Two Standard Regimen for Treatment of Low-risk Medulloblastoma

  NCT07291102· Phase 3· Nationwide Children's Hospital· Source

• Not yet recruiting

  Bone Arches: Performance of Pseudo-scanner Sequences in Segmenting the Extent of the Tumour and in Planning Surgical Resection Using the CT Scan as a Reference

  NCT06988007· Cliniques universitaires Saint-Luc- Université Catholique de Louvain· Source

• Not yet recruiting

  A study on stopping versus continuing beta-blockers in patients with hypertrophic cardiomyopathy treated with mavacamten

  2026-526612-36-00· Phase 4· Ziekenhuis Oost Limburg· Source

• Not yet recruiting

  Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary Fibrosis

  NCT07441408· Phase 3· Bristol-Myers Squibb· Source

• Not yet recruiting

  A Phase 2 trial of AGMB-447 in participants with idiopathic pulmonary fibrosis

  2026-526404-71-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Recruiting

  A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors

  2024-518348-19-00· Phase 1· Novartis Pharma AG· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants with Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  2024-518365-10-00· Phase 3· F. Hoffmann-La Roche AG· Source

• Not yet recruiting

  A pivotal clinical study to investigate the safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis due to Metabolic dysfunction-associated steatohepatitis (MASH)

  2026-525755-82-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Not yet recruiting

  A study to investigate safety and efficacy of efimosfermin compared with placebo in adult participants with compensated cirrhosis (stage F4 fibrosis) due to MASH (NEBULA-2)

  2026-525757-37-00· Phase 3· Glaxosmithkline Research & Development Limited· Source

• Recruiting

  A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN

  NCT07773727· Phase 2· argenx· Source

• Recruiting

  Emotional Reactivity in Severe Alcohol Use Disorder and Major Depressive Disorder Using Eye-tracking, Physiological, and Interoceptive Measures (ERAD)

  NCT07925281· Université Catholique de Louvain· Source

• Recruiting

  A clinical trial to assess the efficacy and safety of ontunisertib compared to placebo in patients with fibrostenosing Crohn’s disease

  2026-525197-19-00· Phase 2· Agomab Spain S.L.U.· Source

• Recruiting

  Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma

  2025-524928-21-00· Phase 3· Revolution Medicines Inc.· Source

• Not yet recruiting

  Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma

  2025-524969-24-00· Phase 3· Revolution Medicines Inc.· Source

• Recruiting

  A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35)

  NCT07843940· Phase 1/2· Boehringer Ingelheim· Source

• Recruiting

  A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

  NCT07768189· Phase 3· Corbus Pharmaceuticals Inc.· Source

• Recruiting

  ENDO-REAL: Endometriosis and Reproductive Enhancement with Letrozole

  2025-524995-53-00· Phase 4· UZ Brussel· Source

• Recruiting

  Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)

  NCT07817875· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Phase 3 Trial of Tarlatamab (SC vs IV) In Extensive-Stage Small Cell Lung Cancer After Platinum based First-line Chemotherapy (DeLLphi-315)

  2026-525489-23-00· Phase 3· Amgen Inc.· Source

• Recruiting

  A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer

  NCT07701941· Phase 1/2· Daiichi Sankyo· Source

• Recruiting

  A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)

  2025-525009-18-00· Phase 3· Incyte Corp.· Source

• Recruiting

  A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia

  NCT07623200· Phase 3· Incyte Corporation· Source

• Not yet recruiting

  A Long-term Study of KT-621 Administered Orally to Participants with Asthma Previously Enrolled in a KT-621 Asthma Study

  2026-526241-98-00· Phase 2· Kymera Therapeutics Inc.· Source

• Recruiting

  A Study Evaluating Ficerafusp Alfa (BCA101) QW in Combination With Pembrolizumab vs Alternative Ficerafusp Alfa Dosing in 1L R or M HNSCC

  NCT07807163· Phase 2· Bicara Therapeutics· Source

• Recruiting

  A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus

  NCT07630714· Phase 2· AstraZeneca· Source

• Not yet recruiting

  Study of Combined GARP:TGF-β1/PD-1 Blockade as a Shock-and-kill Strategy in HIV-1 Cure

  NCT07692932· Cliniques universitaires Saint-Luc- Université Catholique de Louvain· Source

• Not yet recruiting

  Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer.

  2026-525883-17-00· Phase 3· Genmab A/S· Source

• Recruiting

  A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have completed previous zigakibart trials

  2024-519638-22-00· Phase 3· Novartis Pharma AG· Source

• Recruiting

  Inter-Limb Transfer in Acute Stroke

  NCT07822633· University Hospital of Mont-Godinne· Source

• Not yet recruiting

  Phase II study of ezabenlimab in patients with PD-L1-positive head and neck cancer with residual disease detected by ctDNA after chemoradiotherapy

  2025-523575-36-00· Phase 2· Cliniques Universitaires Saint-Luc· Source

• Recruiting

  A Study of ASP2138 Together With Chemotherapy and Pembrolizumab in Adults With Gastric Cancer

  NCT07673887· Phase 3· Astellas Pharma Global Development, Inc.· Source

• Recruiting

  A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

  NCT07492680· Phase 2· Bristol-Myers Squibb· Source

• Recruiting

  Radiotherapy for BCG-unresponsive Non-muscle-invasive Carcinoma in Situ (CIS) Bladder Cancer: an Open-label, Single-arm, Multicentre, Phase 2 Study

  NCT06990061· European Organisation for Research and Treatment of Cancer - EORTC· Source

• Recruiting

  Multicentric study evaluating the usefulness of early PSMA PET scan in metastatic renal cancer requiring standard immunotherapy treatment.

  2024-517098-26-00· Phase 2· Cliniques Universitaires Saint-Luc· Source

• Recruiting

  DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy

  NCT07544654· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

  NCT07665437· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study to Find an Efficacious and Safe Dose of CHF10067 (Zampilimab) in Participants With Idiopathic Pulmonary Fibrosis

  NCT07516951· Phase 2· Chiesi Farmaceutici S.p.A.· Source

• Recruiting

  A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

  NCT07365241· Phase 3· AbbVie· Source

• Recruiting

  Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

  NCT07727694· Universitaire Ziekenhuizen KU Leuven· Source

• Recruiting

  A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis

  NCT07690371· Phase 3· Nektar Therapeutics· Source

• Recruiting

  Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07284602· Phase 3· PureTech· Source

• Recruiting

  A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)

  2025-521587-35-00· Phase 3· Summit Therapeutics Inc.· Source

• Recruiting

  A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction

  NCT07192952· Phase 3· Bayer· Source

• Recruiting

  Crohn’s Head-to-Head Assessing Risankizumab Versus Guselkumab for One Year

  2025-521590-13-00· Phase 3· Janssen Cilag International· Source

• Recruiting

  A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)

  NCT07357727· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07577856· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer

  NCT07525206· Phase 3· AbbVie· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

Showing 50 of 482.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers31 recruiting
• Lung cancer19 recruiting
• Metastatic breast cancer16 recruiting
• Colorectal cancer15 recruiting
• Crohn's disease14 recruiting
• Prostate cancer13 recruiting
• Gastric and oesophageal cancer12 recruiting
• Head and neck cancer11 recruiting
• Melanoma11 recruiting
• Ovarian cancer11 recruiting
• Pancreatic cancer11 recruiting
• Acute myeloid leukaemia9 recruiting
• Endometrial cancer8 recruiting
• Fatty liver disease (MASLD/MASH)7 recruiting
• Multiple myeloma7 recruiting
• Epilepsy6 recruiting
• Idiopathic pulmonary fibrosis6 recruiting
• Stroke6 recruiting
• Triple-negative breast cancer6 recruiting
• Ulcerative colitis6 recruiting
• Acute lymphoblastic leukaemia5 recruiting
• Bladder cancer5 recruiting
• Chronic lymphocytic leukaemia5 recruiting
• Haemophilia5 recruiting
• Liver and biliary tract cancer5 recruiting
• Lupus (SLE)5 recruiting
• Cervical cancer4 recruiting
• Kidney cancer4 recruiting
• Myeloproliferative neoplasms4 recruiting
• Obesity4 recruiting
• Rheumatoid arthritis4 recruiting
• Sarcoma4 recruiting
• Asthma3 recruiting
• Chronic kidney disease3 recruiting
• Coronary artery disease3 recruiting
• Endometriosis3 recruiting
• Heart failure3 recruiting
• IgA nephropathy3 recruiting
• Liver cirrhosis3 recruiting
• Neuroendocrine tumours3 recruiting
• Psoriasis3 recruiting
• Alzheimer disease2 recruiting
• Brain metastases2 recruiting
• Chronic rhinosinusitis with nasal polyps2 recruiting
• Chronic spontaneous urticaria2 recruiting
• Glioblastoma2 recruiting
• Hidradenitis suppurativa2 recruiting
• HIV2 recruiting
• Hodgkin lymphoma2 recruiting
• Multiple sclerosis2 recruiting
• Myelodysplastic syndromes2 recruiting
• Neuroblastoma2 recruiting
• Polycystic kidney disease2 recruiting
• Sarcoidosis2 recruiting
• Amyloidosis1 recruiting
• Atopic dermatitis (eczema)1 recruiting
• Atrial fibrillation1 recruiting
• Bronchiectasis1 recruiting
• Cerebral palsy1 recruiting
• Chronic myeloid leukaemia1 recruiting
• CIDP (chronic inflammatory demyelinating polyneuropathy)1 recruiting
• COPD1 recruiting
• Cushing's syndrome1 recruiting
• Cystic fibrosis1 recruiting
• Deep vein thrombosis and pulmonary embolism1 recruiting
• Depression1 recruiting
• Diffuse large B-cell lymphoma1 recruiting
• High blood pressure1 recruiting
• Hypertrophic cardiomyopathy1 recruiting
• Myasthenia gravis1 recruiting
• Myotonic dystrophy1 recruiting
• Obstructive sleep apnoea1 recruiting
• Primary biliary cholangitis1 recruiting
• Sickle cell disease1 recruiting
• Type 1 diabetes1 recruiting
• Vitiligo1 recruiting

Closed trials

• Recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  NCT06793215· Phase 3· Hoffmann-La Roche· Source

• Completed

  A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease

  NCT06926660· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Study to see How Well and How Safely Different Treatments Work in a Group of Patients with Non-Small Cell Lung Cancer, Chosen Based on their Biomarker Status

  2024-511239-91-00· Phase 2· F. Hoffmann-La Roche AG· Source

• Completed

  A Study of Maribavir in Adults With Post-transplant Cytomegalovirus (CMV) Infection in Belgium

  NCT06677892· Takeda· Source

• Completed

  A study to find a suitable dose of BI 765883 and to test whether it helps people with advanced pancreatic cancer when taken alone or together with chemotherapy

  2023-508998-85-00· Phase 1· Boehringer Ingelheim International GmbH· Source

• Active, not recruiting

  Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC)

  NCT06632951· Phase 2· AbbVie· Source

• Completed

  Clinical Echocardiography and S' Wave for Early Recognition of Acute Coronary Syndrome in the Emergency Department, A Prospective Study

  NCT06860997· Cliniques universitaires Saint-Luc- Université Catholique de Louvain· Source

• Active, not recruiting

  Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis

  NCT06846541· Phase 3· Alumis Inc· Source

• Completed

  A Randomized, Double-blind, Multicenter, Placebo-controlled Study of Adjunctive Aticaprant Plus an Antidepressant for Relapse Prevention in Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia

  2024-511057-22-00· Phase 3· Janssen Cilag International· Source

• Active, not recruiting

  A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial)

  NCT06422884· Phase 2· Endeavor Biomedicines, Inc.· Source

• Completed

  Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

  NCT06433219· Phase 2· EMD Serono Research & Development Institute, Inc.· Source

• Completed

  A study to evaluate the efficacy and safety of subcutaneous sonelokimab compared with placebo in adult participants with moderate to severe hidradenitis suppurativa

  2024-511363-28-00· Phase 3· MoonLake Immunotherapeutics AG· Source

• Completed

  A study to test whether BI 1839100 improves cough in people with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis

  2023-510249-79-00· Phase 2· Boehringer Ingelheim International GmbH· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  A Phase 2 Dose-Finding Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Reduced Ejection Fraction

  2023-508736-62-00· Phase 2· Cardurion Pharmaceuticals Inc.· Source

• Completed

  A First in hUman Study for Resistant Epilepsy With the Vagus Nerve stimulatiOn Device by syneRgia medicAl

  NCT06340802· Synergia Medical· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Moderate to Severe Plaque Psoriasis

  NCT06586112· Phase 3· Alumis Inc· Source

• Active, not recruiting

  A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease

  NCT06544616· Phase 2· Janssen Pharmaceutica N.V., Belgium· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Completed

  EPI-7386 in Combination with Enzalutamide versus Enzalutamide alone in Metastatic Castration-Resistant Prostate Cancer

  NCT05075577· Phase 1/2· Essa Pharma Inc.· Source

• Active, not recruiting

  Study of Zanzalintinib (XL092) + Pembrolizumab vs Pembrolizumab in Subjects With PD-L1 Positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

  NCT06082167· Phase 2/3· Exelixis· Source

• Active, not recruiting

  ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer

  NCT06328738· Phase 1· Enliven Therapeutics· Source

• Terminated

  A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

  NCT06241573· Phase 2/3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

  NCT06346067· Phase 3· Erasca, Inc.· Source

• Completed

  A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis

  NCT06238817· Phase 3· Incyte Corporation· Source

• Completed

  Ventilation Distribution in COPD Patients During Breathing Exercises

  NCT06381973· William Poncin, PT, PhD· Source

• Completed

  A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Rosnilimab in Subjects with Moderate to Severe Rheumatoid Arthritis

  2023-504564-42-00· Phase 2· Anaptysbio Inc.· Source

• Completed

  Regorafenib-pembrolizumab vs. TACE/TARE in intermediate-stage HCC beyond up-to-7.

  NCT04777851· Phase 3· Translational Research In Oncology· Source

• Completed

  GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced Endometrial Cancer

  2022-502453-33-00· Phase 2· Genmab A/S· Source

• Active, not recruiting

  DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer

  NCT06077500· Phase 1· Boehringer Ingelheim· Source

• Completed

  Safety & Effectiveness of Tovinontrine in Chronic Heart Failure With Preserved Ejection Fraction (Cycle-2-PEF)

  NCT06215586· Phase 2· Cardurion Pharmaceuticals, Inc.· Source

• Completed

  A study to investigate efficacy and safety of OG-6219 twice a day in 3 dose levels compared with Placebo in participants aged 18 to 49 with moderate to severe endometriosis-related pain

  2022-501310-57-00· Phase 2· Organon LLC· Source

• Completed

  Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia.

  NCT05962606· Phase 2· Aptarion Biotech AG· Source

• Active, not recruiting

  A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis Suppurativa

  NCT06212999· Phase 3· Incyte Corporation· Source

• Active, not recruiting

  A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment

  NCT06105632· Phase 2· Pfizer· Source

• Completed

  Study of BMS-986466 with Adagrasib with or without Cetuximab in Participants with KRAS G12C-mutant Solid Tumors

  NCT06024174· Phase 1/2· Bristol-Myers Squibb Services Unlimited Company· Source

• Completed

  Evaluation of the Efficacy of TOPIALYSE Baume Protect+ on Atopic Dermatis

  NCT06108570· SVR Group· Source

• Completed

  A study evaluating the safety, tolerability, and efficacy of GLPG5101 in adults with treatment-refractory active systemic lupus erythematosus

  2023-504422-19-00· Phase 1· Galapagos· Source

• Completed

  A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

  NCT05780749· Biokuris s.a.· Source

• Completed

  Mavacamten Impact on Myocardial Structure in Obstructive Hypertrophic Cardiomyopathy

  2022-502316-36-00· Phase 4· Myokardia Inc.· Source

• Completed

  Radiotherapy plus xevinapant or placebo in older patients with locally advanced head and neck cancer

  NCT05724602· Phase 2· European Organisation For Research And Treatment Of Cancer· Source

• Completed

  A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)

  2022-500782-27-00· Phase 1/2· Lakefront Biotherapeutics· Source

• Completed

  A Global, Open-label, Adaptive Design Study to Investigate the Efficacy and Safety of SerpinPC in Subjects With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B (PRESent-2)

  2022-502880-39-00· Phase 2· Apcintex Limited· Source

• Completed

  A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares

  NCT06013969· Phase 4· LEO Pharma· Source

• Completed

  A Phase 3, Double-blind Maintenance Study Assessing Rocatinlimab in Moderate-to-severe AD (ROCKET-ASCEND)

  NCT05882877· Phase 3· Amgen Inc.· Source

• Active, not recruiting

  A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation

  NCT06045806· Phase 3· Celgene· Source

• Terminated

  A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion or Subcutaneous (SC) Injection of Budigalimab and/or ABBV-382

  NCT06032546· Phase 2· AbbVie· Source

• Completed

  A Study of On-treatment ctDNA Changes in Chemo-refractory Colorectal Cancer Patients

  NCT05487248· Jules Bordet Institute· Source

• Terminated

  A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer

  NCT05983367· Phase 2· Inspirna, Inc.· Source

• Completed

  A Study of Lorigerlimab With Docetaxel or Docetaxel Alone in Participants With Metastatic Castration-Resistant Prostate Cancer

  NCT05848011· Phase 2· MacroGenics· Source

Showing 50 of 209.

Conditions

Diseases this institution publishes on or runs trials for.

• Haemophilia15 works · 17 trials
• Chronic rhinosinusitis with nasal polyps12 works · 3 trials
• Polycystic kidney disease4 works · 5 trials
• Giant cell arteritis4 works · 1 trial
• Uterine fibroids4 works · 1 trial
• Polymyalgia rheumatica3 works · 0 trials
• Barrett's oesophagus3 works · 0 trials
• Eosinophilic oesophagitis3 works · 0 trials